X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The Phase 3 clinical study (n=34) showed that patients receiving Tavalisse(Fostamatinib Disodium Hexahydrate) achieved a stable platelet response significantly higher than patients receiving a placebo control for the treatment of adult chronic immune thrombocytopenia.
Lead Product(s): Fostamatinib Disodium Hexahydrate
Therapeutic Area: Immunology Product Name: Tavalisse
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Rigel Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2021
Details:
UPASITA® is administered by intravenous injection to dialysis patients through dialysis circuit and it is possible to adjust the dose and control the medication under the control of physicians or medical staffs.
Lead Product(s): Upacicalcet Sodium
Therapeutic Area: Endocrinology Product Name: Upasita
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sanwa Kagaku Kenkyusho
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2021
Details:
CG0070, a oncolytic immunotherapy in which adenovirus is genetically modified to enhance bladder tumor cells selectivity and anticancer activity, and is injected into the bladder using a urinary tract catheter.
Lead Product(s): CG0070
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: CG Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2021
Details:
If approved, avacopan would be the first-in-class orally administered selective complement 5a receptor inhibitor exerting an anti-inflammatory effect, for the treatment of patients with ANCA-associated vasculitis.
Lead Product(s): Avacopan,Rituximab,Cyclophosphamide
Therapeutic Area: Immunology Product Name: CCX168
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2021
Details:
Primary endpoint was achieved in Phase III clinical study (AJM300/CT3) of AJM300 (nonproprietary name: carotegrast methyl), which EA Pharma and Kissei Pharmaceutical have developed for treatment of ulcerative colitis.
Lead Product(s): Carotegrast Methyl
Therapeutic Area: Gastroenterology Product Name: AJM300
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: EA Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
The financing will support the advancement of CG Oncology’s late-stage clinical programs for its lead oncolytic immunotherapy, CG0070, including an ongoing global Phase 3 trial (BOND3) with CG0070 and a combination Phase 2 study of CG0070 with KEYTRUDA® in the same indication.
Lead Product(s): CG0070
Therapeutic Area: Oncology Product Name: CG0070
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: CG Oncology
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing December 10, 2020
Details:
Under this agreement, Kissei grants Affamed the exclusive right for development and commercialization in China, Taiwan, Hong Kong, Macao and six Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines.
Lead Product(s): KDT-3594
Therapeutic Area: Neurology Product Name: KDT-3594
Highest Development Status: Phase IIProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Affamed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 09, 2020
Details:
The licensing agreement will provide production and commercial prospects for the immunotherapy drug CG0070 from CG Oncology in Japan, South Korea, Taiwan and other Asian countries, except China.
Lead Product(s): CG0070,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: CG Oncology
Deal Size: $140.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement March 26, 2020
Details:
In this paper, to review the results of both phase III clinical trials, a pooled (post hoc) analysis was performed with patients who met the inclusion criteria for the additional phase III trial
Lead Product(s): Rovatirelin
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
